TriangleNCT01085630 · OUTCOME
Progression-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline up to 3 years
What was measured
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
Groups in this outcome
Arm A (Observation)
Patients undergo observation until disease progression.
Arm B (Pemetrexed)
Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.
| Group | Source count |
|---|---|
| Arm A (Observation) | 22 |
| Arm B (Pemetrexed) | 27 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Observation) | 3.0 | Not reported | 2.6 | 11.9 | Not reported |
| Arm B (Pemetrexed) | 3.4 | Not reported | 2.8 | 9.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.6
- upper Limit
- 11.9
- value
- 3.0
- group Id
- OG001
- lower Limit
- 2.8
- upper Limit
- 9.8
- value
- 3.4
- denoms
- counts
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 27
- units
- Participants
- description
- Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients undergo observation until disease progression.
- id
- OG000
- title
- Arm A (Observation)
- description
- Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.
- id
- OG001
- title
- Arm B (Pemetrexed)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Baseline up to 3 years
- title
- Progression-free Survival
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice